What did @drsteveng actually say?
The core argument is this: insulin resistance activates aromatase, aromatase converts testosterone into estrogen, and the result is low testosterone with high estrogen. The punchline is a genuinely useful clinical question: "are the symptoms of low T, really just elevated estrogen?" If that elevated estrogen is driven by insulin resistance and visceral fat, then jumping straight to TRT might make things worse, not better, because you'd just be feeding the aromatase enzyme more raw material.
The creator also lists specific lab markers for metabolic dysfunction, including triglycerides above 100, liver enzymes climbing above 25, a triglyceride-to-HDL ratio above 2, and rising hemoglobin A1C. These are framed as signs of a "metabolically unhealthy person" who needs a different intervention than hormone replacement.
Does the science back this up?
Mostly, yes. The aromatase-insulin resistance connection is one of the better-supported mechanisms in male endocrinology, and the creator gets the basic biology right. The problem is in the absolute framing of some specific numbers and the sweeping claim about causation.
Aromatase (CYP19A1) is expressed in adipose tissue, and visceral fat in particular is associated with higher aromatase activity. Multiple studies confirm that obesity-related hyperinsulinemia upregulates aromatase expression. Giagulli et al. (1994, Journal of Clinical Endocrinology and Metabolism) showed that obese men with low testosterone had significantly higher estradiol and aromatase activity compared to normal-weight hypogonadal men. Corona et al. (2011, European Journal of Endocrinology) found metabolic syndrome was independently associated with lower testosterone in a large meta-analysis. So the mechanism is real and documented.
However, the claim that insulin resistance is "the number one cause of low testosterone in men in the United States" is stated as settled fact. It is a reasonable hypothesis with supporting evidence, but primary hypogonadism, aging-related testicular decline, and other factors also contribute substantially. The epidemiology does not clearly rank insulin resistance above all others.
What did they get wrong (or right)?
The lab thresholds deserve scrutiny. Calling liver enzymes "climbing above 25" as a red flag is unusually aggressive. Standard clinical reference ranges for ALT typically go up to 40-56 U/L depending on the lab, and a value of 26 would not raise an eyebrow in most clinical settings. Using 25 as a cutoff without citing the source feels more like a personal preference than an evidence-based threshold.
The triglycerides above 100 threshold is also tighter than standard clinical definitions of metabolic syndrome, which use 150 mg/dL as the cutoff (National Cholesterol Education Program criteria). Using 100 as a flag is not wrong per se, it may reflect a more preventive posture, but presenting it without context could cause unnecessary alarm in patients with borderline labs.
What he got right: the warning that adding testosterone in an aromatase-heavy environment may accelerate estrogen conversion is pharmacologically sound. Ramasamy et al. (2014, Journal of Urology) documented that TRT in obese men can significantly increase estradiol without proportionate testosterone benefit. The clinical logic holds.
What should you actually know?
If you have symptoms of low testosterone, including fatigue, low libido, brain fog, or mood changes, and your labs show both low testosterone and high estradiol alongside markers of insulin resistance, that is a genuinely different clinical picture than straightforward hypogonadism. It warrants a different conversation with your clinician.
Lifestyle interventions targeting insulin resistance, specifically resistance training, caloric deficit, and improved sleep, have been shown to raise testosterone and lower estradiol in overweight men without any hormonal medication. Khoo et al. (2011, Diabetes Care) demonstrated meaningful testosterone increases in obese men through diet and exercise alone.
That said, insulin resistance and primary hypogonadism can coexist. This is not a binary choice. Some men have both damaged testicular function and metabolic dysfunction. Treating one does not guarantee the other resolves. A clinician should evaluate the full picture, including LH and FSH levels, before deciding whether TRT is appropriate. The creator's framing is a useful counterweight to TRT-first thinking, but it should not become a reason to dismiss hormone therapy when it is genuinely indicated.